Article

Gut Microbiota and Metabolite Dynamics in a MASLD-Associated Liver Fibrosis In Vivo Model: An Integrative Multi-Omic Perspective

2026-02-05

Abstract excerpt

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide. Fibrosis is the main prognostic factor and the last reversible stage before cirrhosis, yet therapeutic options remain limited. Given the strong contribution of gut dysbiosis to MASLD progression, strategies targeting the gut microbiota are of growing interest. This study aims to evaluate th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 264ff8fe-f0ce-5c5d-8376-785211242344
DOI: 10.20944/preprints202602.0461.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Gut Microbiota and Metabolite Dynamics in a MASLD-Associated Liver Fibrosis In Vivo Model: An Integrative Multi-Omic PerspectiveDOI 10.20944/preprints202602.0461.v1Read

The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategySemantic proximity Read

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and ChallengesSemantic proximity Read

Akkermansia muciniphila - A Potential Next-generation Probiotic for Non-alcoholic Fatty Liver DiseaseSemantic proximity Read

The gut microbiome and gut-liver axis in NAFLDSemantic proximity Read

Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patientsSemantic proximity Read

Gut microbiota-derived metabolites tune host homeostasis fateSemantic proximity Read

Bridging the Gut and Liver: Multi-biotics modulate microbiota composition and corroborate transcriptomic improvements in MASLDSemantic proximity Read

Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver DiseaseSemantic proximity Read

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment OptionsSemantic proximity Read

Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and diseaseSemantic proximity Read

Akkermansia muciniphila: A key player in gut microbiota-based disease modulationSemantic proximity Read

Kaempferol Remodels Liver Monocyte Populations and Treats Hepatic Fibrosis in Mice by Modulating Intestinal Flora and Metabolic ReprogrammingSemantic proximity Read